NICE has endorsed idebenone (Raxone) on the NHS to treat Leber’s hereditary optic neuropathy in individuals aged 12 and over, offering hope to around 250 people.
US health insurance coverage decreased significantly, resulting in 25,180 excess deaths before COVID - researchers say this number will triple if the Affordable Care Act is overturned.
A new study, led by researchers at Queen Mary University of London, uses novel biomarkers to predict patient responsiveness to rheumatoid arthritis treatment.
Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences, explain why a herd immunity approach to COVID-19 would include great risk, potentially many deaths, and may simply not work.
Stephen Haynes, Osteopath and IDD Therapy provider, and Clinical Director of Active Therapy Clinic, highlights the causes of a herniated disc and what treatments are available, here.
Emmanouil Avgerinos, Ioannis Fragkos and Yufei Huang explain that for surgical teams, shared experiences and hierarchical structures matter more than you think.
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces Imotopes™, the innovative new immunotherapy approach causing scientists to rethink Type 1 diabetes and its treatment.
Prof Dr Joost Sluijter, Professor, Cellular and Translational Cardiology at University Medical Center Utrecht shares an in-depth perspective on the needs for innovative treatments for heart failure.
Scientists have invented a new drug which could improve life expectancy and quality for patients with hard-to-treat cancers, such as pancreatic cancer.
